Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.45 |
| ▸ | PGR | P06401 | 4/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MASP2 | O00187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17336232 | 0.89 | TSHR (0.43) | TSHRKDM4CDAOLOXL2HRH4 | |
| SCHEMBL4266837 | 0.82 | NR3C1 (0.48) | NR3C1PGRNR3C2KDM4CDAO | |
| Ammonia Solution, Strong SCHEMBL4275950 | 0.81 | NR3C1 (0.47) | NR3C1PGRNR3C2KDM4CDAO | |
| Hydrochloric Acid SCHEMBL4274052 | 0.79 | NR3C1 (0.46) | NR3C1PGRNR3C2KDM4CDAO | |
| SCHEMBL4270694 | 0.72 | SLC6A2 (0.46) | NR3C1PGRNR3C2TSHRDAO | |
| SCHEMBL4275946 | 0.72 | TAAR1 (0.49) | NR3C1PGRNR3C2DAOMASP2 | |
| SCHEMBL12671720 | 0.72 | DAO (0.49) | NR3C1PGRNR3C2DAOHRH4 | |
| SCHEMBL31558601 | 0.72 | LOXL2 (0.56) | NR3C1PGRNR3C2DAOLOXL2 | |
| SCHEMBL28757729 | 0.72 | DAO (0.49) | NR3C1PGRNR3C2DAOHRH4 | |
| SCHEMBL30041114 | 0.72 | DAO (0.53) | NR3C1PGRNR3C2DAOHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154974-B1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-14 | — | — | EP | disclosed |
| US-9796713-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796713-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796713-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-11 | — | — | US | disclosed |
| EP-3154974-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015191401-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015191401-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA6, CHRNA5 | NR3C1 539/4885PGR 841/4885NR3C2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.